Do you want to read an article? Please log in or register.
Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Am J Gastroenterol.
Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Casteele NV, Pai RK, Feagan BG, Sandborn WJ, Jairath V
doi: 10.14309/ajg.
Inflammatory Bowel Disease
Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis
J Crohns Colitis
Magro F, Estevinho MM, Dias CC, Correia L, Lago P, Ministro P, Portela F, Feakins R, Danese S, Peyrin-Biroulet L
doi: 10.1093/ecco-jcc/jjaa176
Esophagus Diseases
Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review
Clin Gastroenterol Hepatol.
Ma C, van Rhijn BD, Jairath V, Nguyen TM, Parker CE, Aceves SS, Furuta GT, Gupta SK, Katzka DA, Safroneeva E, Schoepfer AM, Straumann A, Spergel JM, Pai RK, Feagan BG, Hirano I, Dellon ES, Bredenoord AJ
doi: 10.1016/j.cgh.2018.06.005.
Inflammatory Bowel Disease
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses
Lancet Gastroenterol Hepatol.
Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S
doi: 10.1016/S2468-
Inflammatory Bowel Disease
Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis-a Systematic Review
Clin Gastroenterol Hepatol.
Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL
doi: 10.1016/j.cgh.2018.
Inflammatory Bowel Disease
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Lancet
Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L
doi: 10.1016/S0140-6736(21)00666-8
Irritable Bowel Syndrome (IBS) and Chronic Constipation
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis
Lancet Gastroenterol Hepatol
Bosman M, Elsenbruch S, Corsetti M, Tack J, Simrén M, Winkens B, Boumans T, Masclee A, Keszthelyi D
doi: 10.1016/S2468-1253(21)00023-6
Inflammatory Bowel Disease
A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials
J Crohns Colitis.
Li K, Strauss R, Marano C, Greenbaum LE, Friedman JR, Peyrin-Biroulet L, Brodmerkel C, De Hertogh G
doi: 10.1093/ecco-jcc/jjz022.
RECOMMENDED
Inflammatory Bowel Disease
First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Clin Gastroenterol Hepatol.
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ
doi: 10.1016/j.cgh.2020.01.008.